← Leaderboards
Irene M. Ghobrial
Dana-Farber Cancer Inst
$24,445,801
Attributed
$24,445,801
Total exposure
12
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $6.4M · FY2007–25$10M$7.5M$5M$2.5M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$23,045,801 · 11
FDA$1,400,000 · 1
By mechanism
R01$10,529,977 · 6
U01$9,017,163 · 2
R35$4,108,272 · 1
R21$643,115 · 1
P30$147,274 · 2
Top collaborators
No co-investigators on record.
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Kenneth C Anderson$25,995,373
Others in their field
Top investigators on “Multiple Myeloma”
- David Heimbrook · Leidos Biomedical Research, Inc.$146,380,351
- Larry Arthur$41,717,333
- Charles A Coltman · Southwest Oncology Group$36,988,659
- Kenneth C Anderson · Dana-Farber Cancer Inst$25,497,347
- Nilsa Del Carmen Ramirez · Ohio State University$22,287,552
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$20,250,477
Research focus
Multiple MyelomaMolecularBone MarrowLeadCellsHematologic NeoplasmsPlasma CellsMalignant - DescriptorIn VivoBaseStromal CellsMalignant NeoplasmsIn VitroTherapeutic AgentsMonoclonal Gammopathy Of Uncertain SignificancePreventDiagnosisPlaySamplingMesenchymalBiologicalFutureRegulationGenomics
Grant awards (43)
Myeloma multidimensional precancer atlas$4,437,952
U01 · FY2025 · CA · contact PI
Molecular Prediction of Myeloma Initiation Molecular Prediction of Myeloma Initiation$1,040,400
R35 · FY2025 · CA · contact PI
Molecular prediction of myeloma in African Americans$872,957
U01 · FY2025 · CA · contact PI
Program 06 Lymphoma and Myeloma$33,379
P30 · FY2025 · CA · contact PI
Myeloma multidimensional precancer atlas$1,128,990
U01 · FY2024 · CA · contact PI
Molecular Prediction of Myeloma Initiation Molecular Prediction of Myeloma Initiation$988,380
R35 · FY2024 · CA · contact PI
Molecular prediction of myeloma in African Americans$829,309
U01 · FY2024 · CA · contact PI
Program 06 Lymphoma and Myeloma$40,159
P30 · FY2024 · CA · contact PI
Molecular Prediction of Myeloma Initiation Molecular Prediction of Myeloma Initiation$1,019,592
R35 · FY2023 · CA · contact PI
Molecular prediction of myeloma in African Americans$855,498
U01 · FY2023 · CA · contact PI
Molecular Prediction of Myeloma Initiation Molecular Prediction of Myeloma Initiation$1,059,900
R35 · FY2022 · CA · contact PI
Molecular prediction of myeloma in African Americans$892,457
U01 · FY2022 · CA · contact PI
Program 6: Lymphoma and Myeloma$73,736
P30 · FY2021 · CA · contact PI
(PQ1) Genomic characterization of mesenchymal stromal cells in Monoclonal Gammopathy of Undermined Significance (MGUS)$438,499
R01 · FY2020 · CA · contact PI
(PQ1) Genomic characterization of mesenchymal stromal cells in Monoclonal Gammopathy of Undermined Significance (MGUS)$570,843
R01 · FY2019 · CA · contact PI
(PQ1) Genomic characterization of mesenchymal stromal cells in Monoclonal Gammopathy of Undermined Significance (MGUS)$703,249
R01 · FY2018 · CA · contact PI
Stroma-mediated clonal evolution in Multiple Myeloma$353,770
R01 · FY2018 · CA · contact PI
(PQ1) Genomic characterization of mesenchymal stromal cells in Monoclonal Gammopathy of Undermined Significance (MGUS)$438,499
R01 · FY2017 · CA · contact PI
Stroma-mediated clonal evolution in Multiple Myeloma$353,770
R01 · FY2017 · CA · contact PI
(PQ1) Genomic characterization of mesenchymal stromal cells in Monoclonal Gammopathy of Undermined Significance (MGUS)$438,499
R01 · FY2016 · CA · contact PI
Stroma-mediated clonal evolution in Multiple Myeloma$353,773
R01 · FY2016 · CA · contact PI
The role of miRNA15a and 16-1 in Multiple Myeloma$363,125
R01 · FY2015 · CA · contact PI
Stroma-mediated clonal evolution in Multiple Myeloma$353,786
R01 · FY2015 · CA · contact PI
Stroma-mediated clonal evolution in Multiple Myeloma$353,798
R01 · FY2014 · CA · contact PI
The role of miRNA15a and 16-1 in Multiple Myeloma$352,231
R01 · FY2014 · CA · contact PI
NF-KB and mTOR regulation in Waldenstrom Macroglobulinemia$350,000
R01 · FY2013 · FD · contact PI
The role of miRNA15a and 16-1 in Multiple Myeloma$341,338
R01 · FY2013 · CA · contact PI
The role of miRNA15a and 16-1 in Multiple Myeloma$363,125
R01 · FY2012 · CA · contact PI
NF-KB and mTOR regulation in Waldenstrom Macroglobulinemia$350,000
R01 · FY2012 · FD · contact PI
CXCR4 regulation of tumor progression in Multiple Myeloma$311,124
R01 · FY2012 · CA · contact PI
The role of miRNA15a and 16-1 in Multiple Myeloma$363,125
R01 · FY2011 · CA · contact PI
NF-KB and mTOR regulation in Waldenstrom Macroglobulinemia$350,000
R01 · FY2011 · FD · contact PI
Targeting cell trafficking as a new therapeutic modality for Multiple Myeloma$343,498
R01 · FY2011 · CA · contact PI
CXCR4 regulation of tumor progression in Multiple Myeloma$311,085
R01 · FY2011 · CA · contact PI
Targeting cell trafficking as a new therapeutic modality for Multiple Myeloma$354,054
R01 · FY2010 · CA · contact PI
NF-KB and mTOR regulation in Waldenstrom Macroglobulinemia$350,000
R01 · FY2010 · FD · contact PI
CXCR4 regulation of tumor progression in Multiple Myeloma$320,667
R01 · FY2010 · CA · contact PI
Targeting cell trafficking as a new therapeutic modality for Multiple Myeloma$353,927
R01 · FY2009 · CA · contact PI
CXCR4 regulation of tumor progression in Multiple Myeloma$320,621
R01 · FY2009 · CA · contact PI
Targeting cell trafficking as a new therapeutic modality for Multiple Myeloma$352,995
R01 · FY2008 · CA · contact PI
Regulation of the P13K/AKT pathway in Waldenstrom Macroglobulinemia$321,536
R21 · FY2008 · CA · contact PI
CXCR4 regulation of tumor progression in Multiple Myeloma$320,576
R01 · FY2008 · CA · contact PI
Regulation of the P13K/AKT pathway in Waldenstrom Macroglobulinemia$321,579
R21 · FY2007 · CA · contact PI